Circulating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancer.
about
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets.The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor.Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.
P2860
Circulating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Circulating tumour DNA and res ...... ibitor therapy in lung cancer.
@en
Circulating tumour DNA and res ...... ibitor therapy in lung cancer.
@nl
type
label
Circulating tumour DNA and res ...... ibitor therapy in lung cancer.
@en
Circulating tumour DNA and res ...... ibitor therapy in lung cancer.
@nl
prefLabel
Circulating tumour DNA and res ...... ibitor therapy in lung cancer.
@en
Circulating tumour DNA and res ...... ibitor therapy in lung cancer.
@nl
P2860
P356
P1476
Circulating tumour DNA and res ...... hibitor therapy in lung cancer
@en
P2093
Carles Escriu
P2860
P304
P356
10.21037/JTD.2016.07.96
P577
2016-09-01T00:00:00Z